Esophagogastric Variceal Bleeding in Cirrhotic Portal Hypertension

Esophagogastric variceal bleeding (EVB) is a critical and potentially life-threatening complication of cirrhotic portal hypertension, resulting from elevated portal venous pressure due to liver cirrhosis. Understanding the pathophysiology, diagnosis, management, and prevention of EVB is essential for improving patient outcomes. Here is a comprehensive overview:

### Pathophysiology:

• **Portal hypertension**: Cirrhosis leads to increased resistance to portal blood flow, causing elevated portal pressure. This results in the development of gastroesophageal varices as collateral pathways to relieve pressure.
• **Variceal rupture**: The high-pressure varices, particularly in the esophagus and stomach, are prone to rupture, leading to significant upper gastrointestinal bleeding. This is the deadliest complication of portal hypertension.

---

### Staging of Cirrhosis and Risk Stratification:

• **Compensated cirrhosis (Stages 1–2)**: Patients have no or minimal complications, and the risk of variceal bleeding is lower.
• **Decompensated cirrhosis (Stages 3–5)**: Patients develop complications such as variceal bleeding, ascites, or hepatic encephalopathy. Variceal bleeding risk increases significantly.
• **Late decompensated cirrhosis (Stage 6)**: Associated with very high mortality rates.

---

### Diagnosis:

1. **Noninvasive Tools**:

• Liver stiffness measurement (LSM) using transient elastography:
• **LSM >25 kPa** or **20–25 kPa with low platelet count (<150,000/μL)** strongly suggests clinically significant portal hypertension (CSPH).
• **LSM <15 kPa with normal platelets** rules out CSPH.

2. **Gastroscopy**:

• **Gold standard** for diagnosing varices.
• Detects and grades varices based on size, presence of red wale signs, and bleeding risk.
• Severity classification:
• **Mild**: Straight veins.
• **Moderate**: Tortuous veins or red color (RC+) signs.
• **Severe**: Beady or tumor-like veins with high rupture potential.

3. **LDRf Classification**:

• A Chinese system based on **Location (L)**, **Diameter (D)**, and **Risk factors (Rf)** to guide treatment selection and timing.

---

### Management of Acute Esophagogastric Variceal Bleeding (AEVB):

1. **Initial Stabilization**:

• ICU admission for hemodynamic monitoring and airway protection.
• **Restrictive blood transfusion** targeting hemoglobin levels of 70–80 g/L.
• Correct coagulopathy if needed.

2. **Pharmacologic Therapy**:

• **Vasoactive drugs** (first-line therapy):
• Terlipressin, somatostatin, or octreotide, administered for 3–5 days to reduce portal pressure and control bleeding.
• **Prophylactic antibiotics**:
• Cephalosporins (e.g., ceftriaxone) reduce the risk of infections, early rebleeding, and mortality, especially in Child-Pugh B/C patients.

3. **Endoscopic Therapy**:

• **Esophageal varices**:
• Endoscopic variceal ligation (EVL) is the primary treatment.
• Endoscopic injection sclerotherapy (EIS) is used if EVL is not feasible.
• **Gastric varices**:
• Tissue glue injection (e.g., cyanoacrylate) is the first-line therapy.
• Endoscopic ultrasound (EUS)-guided therapy improves outcomes by achieving superior occlusion rates and reducing recurrence.

4. **Rescue Therapy**:

• **Sengstaken-Blakemore tube**:
• Temporary measure for uncontrolled bleeding when EVL or TIPS is unavailable. It carries high rebleeding and complication rates.
• **TIPS (Transjugular Intrahepatic Portosystemic Shunt)**:
• Definitive rescue therapy for refractory bleeding.
• Early or preemptive TIPS (pTIPS) within 72 hours is beneficial for high-risk patients:
• Child-Pugh B with active bleeding.
• Child-Pugh C (<14 points) with HVPG >20 mmHg.

---

### Prevention Strategies:

#### 1. **Primary Prevention** (Preventing the first bleed):

• **Treating the underlying cause of cirrhosis**:
• Antiviral therapy for HBV/HCV.
• Managing alcohol-related liver disease and nonalcoholic steatohepatitis (NASH).
• Traditional Chinese medicine (TCM) formulas may help slow fibrosis and reduce portal pressure.
• **Nonselective beta-blockers (NSBB)**:
• Not recommended for patients without varices (do not prevent varice formation).
• Recommended for mild varices with high-risk features (e.g., Child-Pugh B/C or RC+ signs). Options include propranolol or carvedilol.
• **Moderate-severe varices**:
• NSBB or EVL can lower the risk of the first bleed.
• EVL is preferred if NSBB are contraindicated or not tolerated.
• **Carvedilol**:
• More potent than propranolol, reducing hepatic venous pressure gradient (HVPG) by up to 20%.

#### 2. **Secondary Prevention** (Preventing rebleeding after the first episode):

• Initiate within 5 days of the initial bleed.
• Combination of **NSBB (e.g., carvedilol)** and **EVL** is the standard approach.
• TIPS is considered for patients with persistent high-risk features or recurrent bleeding despite optimal therapy.

---

### Prognosis:

• **First EVB episode**: High mortality risk, requiring emergency management.
• **Late-stage cirrhosis**: Patients in stages 5–6 have poor outcomes, emphasizing the need for aggressive prevention and timely intervention.

---

### Key Takeaways:

• EVB is a medical emergency that requires a multidisciplinary approach, including pharmacologic, endoscopic, and sometimes surgical interventions.
• Early diagnosis and risk stratification using noninvasive tools and gastroscopy are critical.
• Preventive strategies, including NSBB, EVL, and addressing the underlying cause of cirrhosis, are essential to reduce morbidity and mortality.
• TIPS is an effective rescue therapy for refractory bleeding but is reserved for high-risk patients due to the increased risk of hepatic encephalopathy.